Update on myelin imaging in neurological syndromes

Purpose of review Myelin water imaging (MWI) is generally regarded as the most rigorous approach for noninvasive, in-vivo measurement of myelin content, which has been histopathologically validated. As such, it has been increasingly applied to neurological diseases with white matter involvement, especially those affecting myelin. This review provides an overview of the most recent research applying MWI in neurological syndromes. Recent findings Myelin water imaging has been applied in neurological syndromes including multiple sclerosis, Alzheimer's disease, Huntington's disease, traumatic brain injury, Parkinson's disease, cerebral small vessel disease, leukodystrophies and HIV. These syndromes generally showed alterations observable with MWI, with decreased myelin content tending to correlate with lower cognitive scores and worse clinical presentation. MWI has also been correlated with genetic variation in the APOE and PLP1 genes, demonstrating genetic factors related to myelin health. MWI can detect and quantify changes not observable with conventional imaging, thereby providing insight into the pathophysiology and disease mechanisms of a diverse range of neurological syndromes.

Automated summary

Myelin water imaging (MWI) has been extensively applied in neurological syndromes, including multiple sclerosis, Alzheimer's disease, Huntington's disease, traumatic brain injury, Parkinson's disease, cerebral small vessel disease, leukodystrophies, and HIV. MWI can detect alterations in myelin content, which tend to correlate with cognitive scores and clinical presentation. It has also been associated with genetic variation in the APOE and PLP1 genes, indicating genetic factors related to myelin health. MWI provides valuable insight into the pathophysiology and disease mechanisms of various neurological syndromes.